Prostaglandin analogues get the job done

Article

Travoprost, latanoprost and bimatoprost all significantly reduce intraocular pressure (IOP) and increase ocular perfusion pressure (OPP) in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT), according to report published online ahead of print in Acta Ophthalmologica Scandinavica.

Travoprost, latanoprost and bimatoprost all significantly reduce intraocular pressure (IOP) and increase ocular perfusion pressure (OPP) in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT), according to report published online ahead of print in Acta Ophthalmologica Scandinavica.

Gurbuz Koz and colleagues from the Ankara Numube Education and Research Hospital, Ankara, Turkey enrolled 60 newly diagnosed patients and randomly assigned them to receive either travoprost 0.004% (n=12 with POAG, n=8 with OHT), latanoprost 0.005% (n=11 with POAG, n=9 with OHT) or bimatoprost 0.03% (n=13 with POAG, n=7 with OHT).

At six-months follow-up, IOP had decreased from 26.4±3.3 mmHg to 20.9±1.9 mmHg in the travoprost group, from 26.8±1.3 mmHg to 20.8±2.4 mmHg in the latanoprost group and from 25.8±1.8 mmHg to18.3±1.2 mmHg in the bimatoprost group. A significant increase in OPP was also seen in each group.

The authors of this study concluded that all three prostaglandin analogues are equally efficacious at reducing IOP and increasing OPP in POAG patients.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
Related Content
© 2025 MJH Life Sciences

All rights reserved.